Stockscreener 앱 받기
207.95
0.40%
-1.3672
전일 마감가:
$209.32
열려 있는:
$211.8
하루 거래량:
1.15M
Relative Volume:
1.07
시가총액:
$22.91B
수익:
$10.52B
순이익/손실:
$999.00M
주가수익비율:
24.87
EPS:
8.3628
순현금흐름:
$1.22B
1주 성능:
+8.41%
1개월 성능:
+18.49%
6개월 성능:
+16.68%
1년 성능:
+26.85%
1일 변동 폭
$207.34
$213.20
1주일 범위
$187.58
$213.20
52주 변동 폭
$157.20
$213.20
퀘스트 다이아그노스틱스 Stock (DGX) Company Profile
명칭
Quest Diagnostics Inc
전화
(973) 520-2700
주소
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
207.85 | 23.08B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
509.73 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
215.97 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
618.59 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.00 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
318.71 | 32.29B | 3.11B | 648.81M | 602.27M | 10.88 |
퀘스트 다이아그노스틱스 Stock (DGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-08-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | 개시 | Redburn Atlantic | Buy |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | Jefferies | Buy |
| 2024-10-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | 재개 | Evercore ISI | In-line |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 개시 | Barclays | Equal Weight |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-29 | 개시 | Piper Sandler | Neutral |
| 2023-05-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-23 | 개시 | Evercore ISI | In-line |
| 2022-11-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-04-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-01-28 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-05-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-03-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | 업그레이드 | Argus | Hold → Buy |
| 2020-07-29 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-09 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-04-28 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-04-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-04-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-03-18 | 재개 | Credit Suisse | Neutral |
| 2019-01-31 | 다운그레이드 | Argus | Buy → Hold |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2019-01-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
퀘스트 다이아그노스틱스 주식(DGX)의 최신 뉴스
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics PT to $235 From $210, Maintains Outperform Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics - Benzinga
Quest Diagnostics (DGX): Truist Securities Raises Price Target A - GuruFocus
UBS Raises Price Target for Quest Diagnostics (DGX) to $210 | DG - GuruFocus
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating - marketscreener.com
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News - GuruFocus
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Evercore ISI Adjusts Quest Diagnostics PT to $220 From $190, Maintains In Line Rating - marketscreener.com
Barclays Adjusts Quest Diagnostics PT to $225 From $210, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $219 From $203, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript - Insider Monkey
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220 - GuruFocus
Truist Raises Price Target on Quest Diagnostics to $220 From $205, Keeps Hold Rating - marketscreener.com
Candriam S.C.A. Has $13.69 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised - AlphaStreet News
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026 - Meyka
Quest Diagnostics: Q4 Earnings Snapshot - theheraldreview.com
Why Is Quest (DGX) Stock Soaring Today - Finviz
Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: St - GuruFocus
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue - Finviz
Quest Diagnostics (DGX) Earnings Call Transcript - The Globe and Mail
Quest Diagnostics (DGX) Sees Significant Stock Price Surge - GuruFocus
Quest Diagnostics Incorporated announces an Increase in Equity Buyback - marketscreener.com
Quest Diagnostics Stock Gains 7% Over Increased Profit In Q4 - Nasdaq
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - marketscreener.com
Quest Diagnostics hits 52-week high on outlook (DGX:NYSE) - Seeking Alpha
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Sets New 12-Month High Following Strong Earnings - MarketBeat
Quest Diagnostics stock hits all-time high at $198.00 By Investing.com - Investing.com Canada
Quest Diagnostics stock hits all-time high at $198.00 - Investing.com
Quest Diagnostics Seeks Independent Lab Acquisitions - marketscreener.com
Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand - marketscreener.com
Quest Diagnostics (NYSE:DGX) Issues Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance - MarketBeat
Quest Diagnostics Q4 Adjusted Earnings, Revenue Rise; 2026 Guidance Set -- Shares Up Pre-Bell - marketscreener.com
Quest Diagnostics Posts Strong 2025 Results, Boosts Shareholder Returns - TipRanks
(DGX) Quest Diagnostics Expects 2026 Revenue Range $11.7B$11.82B, vs. FactSet Est of $11.38B - marketscreener.com
(DGX) Quest Diagnostics Expects 2026 Adjusted EPS Range $10.50$10.70, vs. FactSet Est of $10.44 - marketscreener.com
Quest Diagnostics Raises Share Buyback Capacity by $1 Billion - marketscreener.com
Quest Diagnostics Raises Quarterly Dividend by 7.5% to $0.86 a Share, Payable April 20 to Shareholders of Record as of April 6 - marketscreener.com
QUEST DIAGNOSTICS ($DGX) Releases Q4 2025 Earnings - Quiver Quantitative
Quest’s (NYSE:DGX) Q4 CY2025: Beats On Revenue - TradingView
Quest Diagnostics increases dividend 7.5% to $0.86 per quarter, marking 15 consecutive years of dividend increases; announces $1 billion increase in share repurchase authorization - marketscreener.com
퀘스트 다이아그노스틱스 (DGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.80%
자본화:
|
볼륨(24시간):